Kosuke Minaga1, Tomohiro Watanabe2, Yasuyuki Arai3, Masahiro Shiokawa4, Akane Hara1, Tomoe Yoshikawa1, Ken Kamata1, Kouhei Yamashita3, Masatoshi Kudo1. 1. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. 2. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. tomohiro@med.kindai.ac.jp. 3. Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 4. Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Abstract
BACKGROUND: Excessive type I IFN (IFN-I) production by plasmacytoid dendritic cells (pDCs) promotes autoimmunity. Recently, we reported that a prominent feature of both experimental autoimmune pancreatitis (AIP) and human type 1 AIP is pDC activation followed by enhanced production of IFN-I and IL-33. However, the roles played by interferon regulatory factor 7 (IRF7), a critical transcription factor for IFN-I production in pDCs, in these disorders have not been clarified. METHODS: Whole and nuclear extracts were isolated from pancreatic mononuclear cells (PMNCs) from MRL/MpJ mice exhibiting AIP. Expression of phospho-IRF7 and nuclear translocation of IRF7 was examined in these extracts by immunoblotting. Pancreatic expression of IRF7 was assessed by immunofluorescence analysis in experimental AIP. Nuclear translocation of IRF7 upon exposure to neutrophil extracellular traps (NETs) was assessed in peripheral blood pDCs from type 1 AIP patients. Pancreatic IRF7 expression was examined in surgically operated specimens from type 1 AIP patients. RESULTS: IRF7 activation was induced in pancreatic pDCs in experimental AIP. siRNA-mediated knockdown of IRF7 expression prevented AIP development, which was accompanied by a marked reduction in both pancreatic accumulation of pDCs and production of IFN-α and IL-33. Notably, in peripheral blood pDCs isolated from patients with type 1 AIP, nuclear translocation of IRF7 was enhanced as compared with the translocation in pDCs from healthy controls. Furthermore, IRF7-expressing pDCs were detected in the pancreas of patients with type 1 AIP. CONCLUSIONS: These findings suggest that the IRF7-IFN-I-IL-33 axis activated in pDCs drives pathogenic innate immune responses associated with type 1 AIP.
BACKGROUND: Excessive type I IFN (IFN-I) production by plasmacytoid dendritic cells (pDCs) promotes autoimmunity. Recently, we reported that a prominent feature of both experimental autoimmune pancreatitis (AIP) and human type 1 AIP is pDC activation followed by enhanced production of IFN-I and IL-33. However, the roles played by interferon regulatory factor 7 (IRF7), a critical transcription factor for IFN-I production in pDCs, in these disorders have not been clarified. METHODS: Whole and nuclear extracts were isolated from pancreatic mononuclear cells (PMNCs) from MRL/MpJ mice exhibiting AIP. Expression of phospho-IRF7 and nuclear translocation of IRF7 was examined in these extracts by immunoblotting. Pancreatic expression of IRF7 was assessed by immunofluorescence analysis in experimental AIP. Nuclear translocation of IRF7 upon exposure to neutrophil extracellular traps (NETs) was assessed in peripheral blood pDCs from type 1 AIPpatients. Pancreatic IRF7 expression was examined in surgically operated specimens from type 1 AIPpatients. RESULTS:IRF7 activation was induced in pancreatic pDCs in experimental AIP. siRNA-mediated knockdown of IRF7 expression prevented AIP development, which was accompanied by a marked reduction in both pancreatic accumulation of pDCs and production of IFN-α and IL-33. Notably, in peripheral blood pDCs isolated from patients with type 1 AIP, nuclear translocation of IRF7 was enhanced as compared with the translocation in pDCs from healthy controls. Furthermore, IRF7-expressing pDCs were detected in the pancreas of patients with type 1 AIP. CONCLUSIONS: These findings suggest that the IRF7-IFN-I-IL-33 axis activated in pDCs drives pathogenic innate immune responses associated with type 1 AIP.
Authors: Cory A Perugino; Sultan B AlSalem; Hamid Mattoo; Emanuel Della-Torre; Vinay Mahajan; Gayathri Ganesh; Hugues Allard-Chamard; Zachary Wallace; Sydney B Montesi; Johannes Kreuzer; Wilhelm Haas; John H Stone; Shiv Pillai Journal: J Allergy Clin Immunol Date: 2018-05-29 Impact factor: 10.793
Authors: Gina S Garcia-Romo; Simone Caielli; Barbara Vega; John Connolly; Florence Allantaz; Zhaohui Xu; Marilynn Punaro; Jeanine Baisch; Cristiana Guiducci; Robert L Coffman; Franck J Barrat; Jacques Banchereau; Virginia Pascual Journal: Sci Transl Med Date: 2011-03-09 Impact factor: 17.956
Authors: Stan F J van de Graaf; Ulrich Beuers; Lowiek M Hubers; Harmjan Vos; Alex R Schuurman; Robin Erken; Ronald P Oude Elferink; Boudewijn Burgering Journal: Gut Date: 2017-08-01 Impact factor: 23.059
Authors: Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: K Kamata; T Watanabe; K Minaga; A Hara; I Sekai; Y Otsuka; T Yoshikawa; A-M Park; M Kudo Journal: Clin Exp Immunol Date: 2020-09-21 Impact factor: 4.330
Authors: Tommaso Schepis; Sara S De Lucia; Enrico C Nista; Vittoria Manilla; Giulia Pignataro; Veronica Ojetti; Andrea Piccioni; Antonio Gasbarrini; Francesco Franceschi; Marcello Candelli Journal: J Clin Med Date: 2021-12-17 Impact factor: 4.241
Authors: Yan Wang; Lily Guo; Xihui Yin; Ethan C McCarthy; Mandy I Cheng; Aline T Hoang; Ho-Chung Chen; Anushi Y Patel; Denise Allard Trout; Erin Xu; Natalie Yakobian; Willy Hugo; James F Howard; Katherine M Sheu; Alexander Hoffmann; Melissa G Lechner; Maureen A Su Journal: Proc Natl Acad Sci U S A Date: 2022-01-25 Impact factor: 11.205